EP 1481089 A2 20041201 - METHODS BASED ON HORMONE DEPENDENCY OF PRIMARY CANCER CELLS
Title (en)
METHODS BASED ON HORMONE DEPENDENCY OF PRIMARY CANCER CELLS
Title (de)
METHODEN BASIEREND AUF DER HORMONABHÄNGIGKEIT VON PRIMÄREN KREBSZELLEN
Title (fr)
METHODES BASEES SUR LA DEPENDANCE D'HORMONE DES CELLULES CANCEREUSES PRIMAIRES
Publication
Application
Priority
- GB 0300878 W 20030303
- GB 0204967 A 20020302
Abstract (en)
[origin: WO03074732A2] A method for providing information for deciding on a therapeutic strategy for a patient, comprising the step of assessing the activity of a transcription factor in a cell or cells from the patient, comprising the steps of (1) exposing the cell or cells to a recombinant viral vector comprising a reporter gene which comprises a promoter under the control of the transcription factor (transcription factor-dependent promoter); and (2) assessing the expression of the reporter gene in the said cell or cells. A method for characterising the hormone dependency of a primary cancer cell or cells, comprising the steps of (1) exposing the cell or cells to a recombinant viral vector comprising a reporter gene which comprises a hormone-dependent promoter; and (2) assessing the expression of the reporter gene in the said cell or cells. A method for choosing a treatment regime for a patient with a cancer which may be hormone-dependent, comprising the steps of (1) exposing primary cancer cells from the patient to a recombinant viral vector comprising a reporter gene which comprises a hormone-dependent promoter; (2) determining the response of the reporter gene to exposure of the cell or cells to the hormone and/or other test compound; (3) deciding on a treatment regime making use of the information on the reporter gene behaviour. The cancer is preferably breast cancer or endometrial cancer. The recombinant viral vector is preferable a recombinant adenoviral vector. The method may be used to determine whether the patient should be treated using tamoxifen, an aromatase inhibitor, complete estrogen antagonist or chemotherapy.
IPC 1-7
C12Q 1/68; C12N 15/861; A61K 31/00; A61K 31/565; A61K 31/135; A61K 31/70
IPC 8 full level
A61K 31/00 (2006.01); A61K 31/135 (2006.01); A61K 31/565 (2006.01); A61K 31/70 (2006.01); C12Q 1/68 (2006.01); C12Q 1/6897 (2018.01); C12Q 1/6886 (2018.01)
CPC (source: EP)
A61K 31/00 (2013.01); A61K 31/135 (2013.01); A61K 31/565 (2013.01); A61K 31/70 (2013.01); C12Q 1/6897 (2013.01); C12Q 1/6886 (2013.01)
Citation (search report)
See references of WO 03074732A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 03074732 A2 20030912; WO 03074732 A3 20040108; AU 2003216985 A1 20030916; AU 2003216985 A8 20030916; EP 1481089 A2 20041201; GB 0204967 D0 20020417
DOCDB simple family (application)
GB 0300878 W 20030303; AU 2003216985 A 20030303; EP 03712307 A 20030303; GB 0204967 A 20020302